Compare Moody's Corporation (MCO) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Novavax Inc — how do they compare? Moody's Corporation trades at $464.23 (market cap $79.44B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Moody's Corporation is far larger — about 43.6× Novavax Inc's market cap, and Moody's Corporation pays a 0.9% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 132 Days and Novavax Inc for 59 Days on average.
| MCO | NVAX | |
|---|---|---|
Market Cap | $79.44B | $1.82B |
Volume | 526,684 | 6,198,505 |
Sector | Financials | Health |
52-Week High | $539.61 | $12.75 |
52-Week Low | $412.23 | $6.22 |
Typical Hold Time | 132 Days | 59 Days |
Enterprise Value | $85.46B | $1.39B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCO trades at $458.69, up 2.01% today, with a bearish technical signal but strong fundamentals including 34.25% net income margin and 80.15% ROE. Recent earnings beats and a consensus price target of $536.40 suggest upside potential. The company announced a minority stake in PhilRatings and a new credit risk model with Allvue, expanding its Asia-Pacific presence and product offerings.
Outlook is positive given consistent earnings growth and strategic expansions, though high valuation multiples and bearish technical indicators near-term pose risks. Analyst consensus is bullish with 56% buy ratings, but investors should monitor debt levels and macroeconomic sensitivity.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
